Erasca, Inc. (ERAS)
Last updated: 2026-10-23 09:21:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Erasca, Inc. (ERAS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.02, with a market capitalization of $5.07B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.11 to $24.28. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$5.07B | |
$14.37 | |
$24.47 | |
$1.01 | |
$14.04 | |
6.02K | |
4.35M | |
-- | |
$24.28 | |
$2.11 | |
-- | |
-- |
Erasca, Inc. (ERAS) Pre-Market Stock Price
Erasca, Inc. (ERAS) is trading at $14.02 in pre-market trading as of 2026-10-23 08:54:00, down 0.15% ($0.02) from the previous close of $14.04
Pre-market trading shows how investors are pricing ERAS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Erasca, Inc. (ERAS) 7-Day Stock Price Change
Over the past seven days, Erasca, Inc. (ERAS) moved from $14.70 to $14.02, representing a decline of 4.63% ($0.68).
The stock traded between $13.10 and $15.26 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 4.99 million shares, down versus the previous seven-day period, indicating lower trading activity.
ERAS 52-Week Price Position
Position in Range: 53.7%
ERAS is currently trading at $14.02, placing it 53.7% of the way from its 52-week low of $2.11 to its 52-week high of $24.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Erasca, Inc. (ERAS)?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Erasca, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Erasca, Inc. (ERAS) Stock on MEXC
Eligible investors can buy real shares of Erasca, Inc. (ERAS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Erasca, Inc. (ERAS) stock price today?
2.Is ERAS stock going up or down today?
3.What is ERAS pre-market price?
4.What is ERAS after-hours price?
5.Is ERAS stock trading now?
6.Where does ERAS sit relative to its 52-week high and low?
7.What sector is Erasca, Inc. in?
8.What is Erasca, Inc.'s market capitalization and where is it listed?
9.How is ERAS valued in terms of P/E ratio and EPS?
10.Does Erasca, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ERAS Stock Calculator
Estimate the value between ERAS shares and USD.
ERAS Shares to USD
1.00 ERAS shares = 14.019 USD
Calculations are estimates based on the latest available price and are for reference only.


